Cancer Family
Stromal Neoplasm
CI-CAN-00000360Explore in graph →
Non-malignant52 active trials2 approved drugs89 evidence items
- NCIt
- C6781
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000360Explore in graph →
Clinical trials
355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03165721 | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03624244 | Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)(BFR-ESS) | recruiting | Phase 2 | 40 | Centre Leon Berard |
| 1 |
| Feb 17, 2026 |
| clinicaltrials |
| NCT07411118 | RCT of EFTR Versus STER for GIST Treatment | recruiting | N/A | 136 | Chinese University of Hong KongOTHER | 4 | Feb 13, 2026 | clinicaltrials |
| NCT07405125 | Safety of Robotic Surgery for GISTs at Special Anatomic Sites | recruiting | N/A | 182 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05381753 | Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World | completed | — | 61 | CStone PharmaceuticalsINDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07394413 | Surgical Handling of Fertility-preserving Treatments for Cervical Adenocarcinomas(SHAFT) | not yet recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03673501 | A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib(INTRIGUE) | active not recruiting | Phase 3 | 453 | Deciphera Pharmaceuticals, LLCINDUSTRY | 22 | Feb 5, 2026 | clinicaltrials |
| NCT06630234 | A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) | recruiting | Phase 1 / Phase 2 | 120 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06655246 | A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | recruiting | Phase 1 | 157 | Kura Oncology, Inc.INDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05245968 | A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) | active not recruiting | Phase 1 | 78 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 5 | Jan 20, 2026 | clinicaltrials |
| NCT01048281 | Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma | recruiting | — | 100 | Stanford UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05734105 | A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib(INSIGHT) | active not recruiting | Phase 3 | 54 | Deciphera Pharmaceuticals, LLCINDUSTRY | 15 | Dec 17, 2025 | clinicaltrials |
| NCT07273045 | A Comprehensive, Multinational GIST Registry(reGISTTry) | not yet recruiting | — | 1,000 | Universität Duisburg-EssenOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06619275 | Ripretinib (QINLOCK®) According to Current SmPC(INTEREST) | completed | — | 10 | iOMEDICO AGINDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT01991379 | MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | active not recruiting | Phase 1 / Phase 2 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06208748 | SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST | active not recruiting | Phase 2 | 40 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | terminated | Phase 1 | 122 | Novartis PharmaceuticalsINDUSTRY | 9 | Sep 30, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT04258956 | A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy(AXAGIST) | completed | Phase 2 | 58 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05366816 | ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST | recruiting | Phase 2 | 48 | University of MiamiOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT01907607 | Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib(CYCLIGIST) | completed | Phase 2 | 29 | Institut BergoniéOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07109024 | Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST)(PATHFINDERS) | not yet recruiting | — | 40 | Universität Duisburg-EssenOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05385549 | 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk | recruiting | Phase 2 | 35 | Asan Medical CenterOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07106411 | CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study | not yet recruiting | — | 288 | Huazhong University of Science and TechnologyOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06772233 | A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment | not yet recruiting | Phase 2 | 100 | Peking UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07078136 | Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis | recruiting | — | 130 | Huazhong University of Science and TechnologyOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT07072143 | An International Study on Pediatric Patients With Rare Tumors.(PARTNER) | recruiting | — | 6,250 | Azienda Ospedaliera di PadovaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04811196 | A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | completed | Phase 1 | 56 | University Health Network, TorontoOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT03493152 | Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019) | no longer available | — | — | The University of Texas Health Science Center at San AntonioOTHER | 0 | May 28, 2025 | clinicaltrials |
| NCT03716089 | Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site | recruiting | — | 250 | Fujian Medical UniversityOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05804331 | The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study(ANZ UGI) | recruiting | — | 500 | Western Sydney Local Health DistrictOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT04181970 | Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK((SELNET)) | recruiting | — | 5,000 | Grupo Espanol de Investigacion en SarcomasOTHER | 8 | Mar 21, 2025 | clinicaltrials |
| NCT04282980 | A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) | completed | Phase 2 | 39 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT05440357 | Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study | unknown | — | 100 | Xinhua Zhang, MDOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT05461664 | Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA | recruiting | — | 74 | Xinhua Zhang, MDOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT05464875 | A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors | recruiting | — | 74 | Xinhua Zhang, MDOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06038552 | Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM | completed | — | 238 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06431451 | The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients with Advanced GISTs | unknown | — | 60 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT02401815 | CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 51 | Cogent Biosciences, Inc.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT00780494 | Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma | completed | Phase 2 | 35 | Stanford UniversityOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03241745 | A Study of Nivolumab in Selected Uterine Cancer Patients | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04908176 | A Drug-drug Interaction Study of Avapritinib and Midazolam | completed | Phase 1 | 10 | Blueprint Medicines CorporationINDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT04825574 | Study for Patients Previously Treated in Avapritinib Clinical Trials | completed | Phase 4 | 2 | Blueprint Medicines CorporationINDUSTRY | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04584008 | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics(VISIONARY) | active not recruiting | N/A | 600 | Peking UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06628739 | Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes | completed | — | 168 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT04530981 | A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST | completed | Phase 1 | 13 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01863745 | Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment | completed | Phase 2 | 15 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 19, 2024 | clinicaltrials |
| NCT01294202 | A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST | completed | Phase 2 | 26 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Feb 18, 2026source: clinicaltrials